Skip to main content

Advertisement

Table 4 Comparison between the early termination and continuous treatment groups

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  Early termination group (n = 16) Continuous treatment group (n = 14) p value
Baseline characteristics
 Age 73.0 [67.5, 76.5] 71.5 [68.0, 74.0] 0.601
 Gender (male/female) 13/3 11/3 1.00
 Physique
  Body weight (kg) 52.6 [47.7, 57.8] 58.5 [54.5, 66.3] 0.048
  Body mass index 19.1 [17.2, 21.1] 21.9 [21.0, 24.2] 0.007
  Body surface area (DuBois, m2) 1.58 [1.47, 1.66] 1.65 [1.51, 1.77] 0.19
 Laboratory data
  Creatinine (mg/dL) 0.81 [0.68, 0.87] 0.74 [0.68, 0.86] 0.852
  Krebs von den Lungen-6 (U/mL) 1021 [732, 1518] 1047 [845, 2106] 0.678
  Surfactant protein D (ng/dL) 315 [186, 393] 420 [273, 553] 0.081
 Lung function test
  % Forced vital capacity (%) 48.5 [36.5, 58.6] 56.6 [50.1, 69.7] 0.212
  % DLco (%) 45.1 [41.9, 58.6] 42.4 [37.8, 53.3] 0.499
Administration history of pirfenidone
 Administration period (day) 238 [146, 468] 262 [127, 397] 0.934
 Reason for discontinuation (%)
  decline of forced vital capacity 6 (37.5%) 9 (64.3%) 0.272
  adverse events 10 (62.5%) 5 (35.7%)  
 Maintenance dose (%)
  < 1200 mg 8 (50.0%) 2 (14.3%) 0.099
  1200 mg 5 (31.2%) 11 (78.6%)  
  1800 mg 3 (18.8%) 1 (7.1%)  
  1. Categorical data are presented as numbers (percentages), whereas continuous data are presented as medians (interquartile ranges). Fisher’s exact test was used to compare categorical data, and the Mann–Whitney U test was used to compare continuous data
  2. Abbreviation: DLCO diffusing capacity for lung carbon monoxide